Boehringer Ingelheim’s survodutide shows promise in liver fibrosis treatment Phase 2 trial reveals significant improvement in MASH patients
Resolution unveils data for liver disease treatment at EASL 2024 Extended phase 2 study highlights macrophage cell therapy’s efficacy